Shots:

• The NMPA’s approval is based on P-III IMpower133 study assessing Tecentriq + CT vs PBO + CT as monothx. in 403 CT naïve patients in a ratio (1:1) with ES-SCLC
• The P-III IMpower study results: OS (12.3 vs 10.3 mos.); mPFS (5.2 vs 4.3 mos.); follow up analysis @18mos. OS rate (34% vs 21%); safety profile is consistent with the previous profile
• Tecentriq is a mAb targeting PD-L1- blocking its interaction with both PD-1 and B7.1 receptors.  In Jan’2020- NMPA has accepted sBLA for Tecentriq + Avastin (bevacizumab) for unresectable HCC- prior not treated with systemic therapy

Click here ­to­ read full press release/ article 

 Ref: Roche | Image: Roche